Search
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929] … [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A13448] Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and … Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island
Categories: Mammalian target of rapamycin (mTOR) kinase inhibitorsProducts: RAPAMUNE TABLET 1 mg, RAPAMUNE TABLET 2 mgDipotassium phosphate
go.drugbank.com/drugs/DB09414ApprovedInvestigationalDipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.
Categories: Compounds used in a research, industrial, or household settingBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide
Neon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Other clinical applications of neon, such as a radiotherapy in various cancers [A32763], have been studied.
Mixtures: Co-NE-O2-N2 MixtureBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalwith unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients
Products: MEKTOVI® 15 MG TABLETAS RECUBIERTAS, Mektovı 15 mg Film Kaplı Tablet, 84 ADETAmmonia N-13
go.drugbank.com/drugs/DB09326ApprovedThe active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawnconventional or biologic therapy. … Darvadstrocel is a suspension of expanded human allogeneic adipose-derived mesenchymal stem cells extracted from the subdermal adipose tissue of healthy donors via liposuction.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted...
Categories: Compounds used in a research, industrial, or household settingLisuride
go.drugbank.com/drugs/DB00589ApprovedAn ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome